Uniqure NV (NASDAQ:QURE) Director Philip Astley-Sparke sold 5,000 shares of the stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $30.39, for a total value of $151,950.00. Following the completion of the transaction, the director now owns 23,252 shares in the company, valued at approximately $706,628.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
NASDAQ:QURE traded down $0.69 during mid-day trading on Thursday, reaching $28.93. 27,116 shares of the stock were exchanged, compared to its average volume of 596,626. The company has a market capitalization of $1.10 billion, a PE ratio of -9.84 and a beta of 0.81. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of 0.05. Uniqure NV has a 1 year low of $14.68 and a 1 year high of $43.23.
Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.03. The firm had revenue of $3.15 million for the quarter, compared to the consensus estimate of $3.37 million. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%. As a group, sell-side analysts anticipate that Uniqure NV will post -2.57 EPS for the current fiscal year.
A number of research analysts have recently commented on QURE shares. Janney Montgomery Scott reiterated a “buy” rating on shares of Uniqure in a report on Wednesday, August 8th. BidaskClub upgraded Uniqure from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 9th. HC Wainwright set a $42.00 price target on Uniqure and gave the stock a “buy” rating in a research note on Thursday, August 9th. Cantor Fitzgerald set a $58.00 price target on Uniqure and gave the stock a “buy” rating in a research note on Saturday, August 11th. Finally, Cowen restated a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Uniqure has an average rating of “Buy” and an average target price of $55.67.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Uniqure NV (QURE) Director Sells 5,000 Shares of Stock” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/12/06/insider-selling-uniqure-nv-qure-director-sells-5000-shares-of-stock.html.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Story: Insider Trading – What You Need to Know
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.